Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
May 16th, 2021
6.6K views
Monitoring changes in the melting temperature of a target protein (i.e., thermal shift assay, TSA) is an efficient method for screening fragment libraries of a few hundred compounds. We present a TSA protocol implementing robotics-assisted nano-Differential Scanning Fluorimetry (nano-DSF) for monitoring intrinsic tryptophan fluorescence and light back-scattering for fragment screening.
Overview
This article details a protocol for high-throughput fragment screening using nano-Differential Scanning Fluorimetry (nano-DSF) to monitor protein thermal stability. The method enables efficient identification of fragment binders by observing shifts in protein melting temperature (Tm) and is applicable to a wide range of protein targets. The protocol leverages a nanoliter robotic dispenser for sample preparation and provides step-by-step guidance for data acquisition and analysis.
Key Study Components
Area of Science
- Protein biochemistry
- Structural biology
- Drug discovery
Background
- Thermal shift assays (TSAs) assess protein stability by measuring changes in melting temperature under different conditions.
- nano-DSF is a label-free technique that monitors intrinsic tryptophan fluorescence to detect protein unfolding.
- Fragment-based lead discovery relies on identifying small molecules that bind and stabilize or destabilize target proteins.
- Efficient screening methods are essential for early-stage drug discovery campaigns.
Purpose of Study
- To present a robust, efficient protocol for fragment screening using nano-DSF.
- To demonstrate the use of a nanoliter robotic dispenser for high-throughput sample preparation.
- To illustrate the application of this method across multiple protein targets relevant to drug discovery.
Methods Used
- Preparation of protein and fragment plates, including thawing, centrifugation, and dispensing using a robotic system.
- Transfer of protein-fragment mixtures into capillaries for nano-DSF analysis.
- Thermal denaturation measurements by monitoring intrinsic tryptophan fluorescence and aggregation via light back-scattering.
- Data acquisition using the Prometheus instrument and subsequent analysis of Tm shifts.
Main Results
- Screening of the DSi-Poised fragment library (768 compounds) was successfully performed using nano-DSF.
- Both stabilizing and destabilizing fragment hits were identified for different protein targets, including Hec1, Mps1, and SARS-CoV-2 3C-like protease.
- For the SARS-CoV-2 protease, all fragments tested had a destabilizing effect, informing further drug development efforts.
- The protocol proved to be rapid, cost-effective, and adaptable to various fragment libraries and protein targets.
Conclusions
- nano-DSF is a valuable tool for fragment-based screening, requiring minimal protein and no labeling.
- The described protocol enables efficient, high-throughput identification of fragment binders.
- This approach can be readily adapted to other fragment libraries and instruments, supporting diverse lead discovery campaigns.
Frequently Asked Questions
What is the main advantage of using nano-DSF for fragment screening?
nano-DSF allows label-free, high-throughput screening of fragment libraries using minimal protein, making it efficient and broadly applicable for early-stage drug discovery.
How are protein and fragment samples prepared for nano-DSF analysis?
Protein and fragment solutions are dispensed into crystallization plates using a nanoliter robotic dispenser, then transferred into capillaries for measurement.
What does a shift in melting temperature (Tm) indicate in this assay?
A positive shift in Tm suggests protein stabilization by a fragment, while a negative shift indicates destabilization, both of which can inform fragment binding.
Can this protocol be used with any protein target?
Yes, the protocol is suitable for almost all protein targets, provided sufficient protein quality and concentration are available.
What are the limitations of nano-DSF fragment screening?
While nano-DSF efficiently identifies fragment binders, it does not provide structural information about binding sites; complementary methods like NMR or X-ray crystallography are needed for detailed characterization.
How does this method contribute to COVID-19 drug discovery?
Screening fragments against the SARS-CoV-2 3C-like protease identified destabilizing hits, guiding the development of new antiviral compounds.
Is the protocol adaptable to other fragment libraries or instruments?
Yes, the described workflow can be easily transferred to different fragment collections or adapted for use with other nano-DSF instruments.
Executive Industry Relevance
nano-Differential Scanning Fluorimetry (nano-DSF) enables rapid, label-free screening of fragment libraries for early-stage lead identification, using minimal protein and supporting high-throughput workflows. This approach enhances predictive confidence in fragment-based drug discovery by providing quantitative thermal stability data across diverse protein targets. Integrating nano-DSF into discovery pipelines accelerates triage of fragment hits and informs downstream structural and functional validation.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables direct assessment of fragment binding through protein thermal stability shifts.
- Supports functional target validation by distinguishing stabilizing and destabilizing fragment effects.
- Facilitates rapid triage of fragment hits for further mechanistic or structural studies.
Screening & Assay Development
- Prepares validated protein-fragment mixtures for downstream biophysical or structural workflows.
- Delivers quantitative, reproducible Tm measurements for robust hit identification.
- Supports scalable, high-throughput screening using automated sample preparation and analysis.
Translational & Preclinical Research
- Aligns fragment screening outputs with disease-relevant protein targets, including viral proteases.
- Provides continuity from fragment identification to preclinical candidate selection.
- Enables risk-adjusted advancement of fragment-derived leads based on quantitative binding data.
Pipeline & Workflow Integration
nano-DSF fragment screening fits at the intersection of early discovery and lead identification, bridging biophysical hit validation and downstream structural elucidation.
- Discovery Biology: Quantifies protein-ligand interactions to support hypothesis-driven target engagement studies.
- Screening: Offers reproducible, high-throughput Tm shift data for reliable fragment evaluation.
- Analytics: Provides clear, quantitative readouts for comparing fragment effects across multiple targets.
- Translational Research: Connects fragment binding data to disease-relevant targets, informing preclinical prioritization.
- Enterprise Reuse: Adaptable protocol supports diverse fragment libraries and protein systems across discovery programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in fragment binding and target validation.
- Operational Value: Standardizes and streamlines fragment screening with minimal protein requirements.
- Strategic Value: Accelerates go/no-go decisions and reduces resource expenditure on non-viable fragments.
- Portfolio Impact: Enables risk-adjusted prioritization of fragment-derived leads for further development.
Implementation Considerations
- Requires expertise in protein biochemistry and biophysical assay setup.
- Needs access to nano-DSF instrumentation and automated liquid handling systems.
- Demands consistent protein quality and concentration for reliable results.
- Protocol is adaptable to various fragment libraries and compatible with most protein targets.
- Complementary structural methods may be needed for detailed binding site characterization.
Biopharma FAQs
Why does null hypothesis testing matter for Tm shift-based fragment validation?
Null hypothesis testing ensures that observed Tm shifts in nano-DSF assays reflect true fragment binding rather than random variation, supporting confident target validation and reducing false positives in lead discovery.
How does independent variable isolation improve fragment screening with nano-DSF?
Isolating variables such as fragment concentration and protein quality allows clear attribution of Tm changes to specific fragment-protein interactions, enhancing the reliability of screening outputs for downstream decision-making.
What do quantitative Tm measurements enable in fragment-based discovery?
Quantitative Tm data enable direct comparison of fragment effects across targets, facilitate ranking of hits, and provide actionable metrics for advancing fragments to structural or functional follow-up studies.
Why are replication requirements critical for cross-functional fragment screening?
Replication ensures that Tm shifts are reproducible and robust, supporting cross-team confidence in fragment hits and enabling seamless integration with structural biology and medicinal chemistry workflows.
What statistical analysis capabilities are required before implementing nano-DSF screening?
Robust statistical analysis is needed to distinguish significant Tm shifts from background noise, set hit thresholds, and validate fragment binding, ensuring reliable data for portfolio advancement decisions.
